SCHEMBL2862881

SCHEMBL2862881

CCCOc1cccc(-c2csc(Cn3cc(C(=O)O)cn3)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 2/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
DHODH Q02127 1/20 0.42
CSNK2A1 P68400 1/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
EGLN1 Q9GZT9 2/20 0.41
FABP1 P07148 1/20 0.41
NR1H4 Q96RI1 2/20 0.40
CTSA P10619 1/20 0.40
PTPN11 Q06124 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PPARD Q03181 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875775 0.93 RXRA (0.50) ALDH1A1HTTSMN1; SMN2KDM4EGAA
SCHEMBL1197885 0.92 CSNK2A1 (0.43) KMT2AALDH1A1HTTSMN1; SMN2DHODH
SCHEMBL12875812 0.90 L3MBTL1 (0.42) KMT2AALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL2857010 0.89 ALKBH1 (0.48) ALDH1A1SMN1; SMN2KDM4ECSNK2A1EGLN1
SCHEMBL1197517 0.89 CSNK2A1 (0.53) KMT2AALDH1A1HTTSMN1; SMN2LMNA
SCHEMBL2879638 0.88 HDAC3 (0.46) KMT2AALDH1A1HTTSMN1; SMN2GAA
SCHEMBL1198990 0.87 EGLN1 (0.52) EGLN1NR1H4PPARDPPARA
SCHEMBL1198543 0.87 GAA (0.44) KMT2AALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL1198881 0.86 ALDH1A1 (0.43) KMT2AALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL2859048 0.86 HDAC3 (0.40) KMT2AALDH1A1SMN1; SMN2KDM4ECSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed
WO-2009123316-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF 武田薬品工業株式会社 (JP) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A KMT2A 3197/4885ALDH1A1 1037/4885HTT 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.